TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19439099

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for children (KIDNET)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Meditation-relaxation (MED-RELAX)
Number of subjects: 31
Study: 16890599

Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 72 weeks (group B)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 48 weeks (group A)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a plus ribavirin for 24 weeks (group C)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a plus ribavirin for 48 weeks (group D)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a plus ribavirin for 72 weeks (group B) in genotype 1-infected patients
Number of subjects: 326

Group type: COMPARATOR
Intervention: Peginterferon-alfa2a plus ribavirin for 48 weeks (group A) in genotype 1-infected patients
Number of subjects: 326
Study: 15083371

Group type: EXPERIMENTAL
Intervention: Submaximal fatigue protocol (20% MVC) in men
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Submaximal fatigue protocol (20% MVC) in women
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between genders
Number of subjects: 20
Study: 11473066

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 9778330

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography with E/Ea ratio
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 100
Study: 7611921

Group type: COMPARATOR
Intervention: Captopril 50 mg tid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg tid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 3234469

Group type: EXPERIMENTAL
Intervention: Maprotiline (50 mg b.d. for 15 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nomifensine (50 mg b.d. for 15 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alcohol (1 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Antidepressants (Maprotiline and Nomifensine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 8
Study: 29948023

Group type: COMPARATOR
Intervention: INTP5 (3 mg/0.3 ml)
Number of subjects: 344

Group type: COMPARATOR
Intervention: INTP5 (6 mg/0.6 ml)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Neulasta (3 mg/0.3 ml)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Neulasta (6 mg/0.6 ml)
Number of subjects: 344

Group type: COMPARATOR
Intervention: INTP5
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Neulasta
Number of subjects: 344

Group type: COMPARATOR
Intervention: INTP5 and Neulasta
Number of subjects: 344
Study: 26515228

Group type: COMPARATOR
Intervention: Sleeping-bags
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 80
Study: 23605244

Group type: EXPERIMENTAL
Intervention: TLLS+ (transmeatal low-power laser stimulation at 5 mW, 650 nM wavelength for 20 min daily and oral betahistine 24 mg twice per day for 10 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: TLLS- (placebo device and oral betahistine 24 mg twice per day for 10 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison between TLLS+ and TLLS- groups
Number of subjects: 43
Study: 22874110

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium carbonate (CaC)
Number of subjects: 50
Study: 19838644

Group type: EXPERIMENTAL
Intervention: Intraoperative cerebral microembolization during THA
Number of subjects: 45
Study: 18513916

Group type: EXPERIMENTAL
Intervention: Informed choice invitation based on General Medical Council guidelines and combined with a decisional balance sheet
Number of subjects: 417

Group type: COMPARATOR
Intervention: Traditional invitation
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 417
Study: 16193258

Group type: EXPERIMENTAL
Intervention: Riluzole and minocycline (100 mg i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Riluzole (50 mg b.i.d.)
Number of subjects: 20
Study: 12901286

Group type: EXPERIMENTAL
Intervention: 3MU alpha N1‐IFN daily for 10 days every 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reduced dosage of alpha N1‐IFN or stopped interferon therapy or received 30MU dose at 6‐month intervals
Number of subjects: 20
Study: 10028075

Group type: EXPERIMENTAL
Intervention: Azithromycin (750 mg loading dose followed by 250 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/d)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 8684870

Group type: EXPERIMENTAL
Intervention: Brand erythromycin estolate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Brand trimethoprim‐sulfamethoxazole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Generic cephalexin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Generic erythromycin ethylsuccinate/sulfisoxazole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Generic penicillin V potassium
Number of subjects: 42
Study: 1830321

Group type: EXPERIMENTAL
Intervention: ACTH‐(1‐24) stimulation
Number of subjects: 21
Study: 6882332

Group type: EXPERIMENTAL
Intervention: 15% O2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 13% O2
Number of subjects: 6

Group type: COMPARATOR
Intervention: 21%, 19%, 17% O2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 15%, 13% O2
Number of subjects: 6
Study: 31835477

Group type: EXPERIMENTAL
Intervention: Full intervention (SuperFIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29419337

Group type: EXPERIMENTAL
Intervention: Hatha Yoga intervention (twice‐weekly, 60‐minute sessions for 8 weeks)
Number of subjects: 10
Study: 27449643

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (monthly or every 2 months after 3 monthly injections)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Monthly ranibizumab
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Fellow eyes
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Study eyes
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Fellow eyes and study eyes
Number of subjects: 843
Study: 25455833

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 199
Study: 23469597

Group type: EXPERIMENTAL
Intervention: Dujieqing Oral Liquid (DJQ) combined with conventional chemotherapy (20 mL each time, three times daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dujieqing Oral Liquid (DJQ) combined with conventional chemotherapy
Number of subjects: 60
Study: 19861364

Group type: EXPERIMENTAL
Intervention: Confirmed awareness patients (n=7)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls (n=25)
Number of subjects: 38
Study: 18030066

Group type: EXPERIMENTAL
Intervention: Prasugrel 60-mg loading dose (LD) followed by 10-mg daily maintenance dose (MD)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Prasugrel 60-mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Prasugrel 10-mg MD
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clopidogrel 600-mg
Number of subjects: 41
Study: 15649107

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12576937

Group type: EXPERIMENTAL
Intervention: Strict normalization of blood glucose (80‐110 mg/dL) with insulin infusion
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Conventional approach (blood glucose levels at 180‐200 mg/dL)
Number of subjects: 1548
Study: 10697394

Group type: EXPERIMENTAL
Intervention: Insulin binding to erythrocyte receptors in patients with essential hypertension
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin concentration in patients with essential hypertension
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin degradation by erythrocytes
Number of subjects: 23

Group type: COMPARATOR
Intervention: Correlation between body weight and insulin concentration
Number of subjects: 23
Study: 8605753

Group type: EXPERIMENTAL
Intervention: iodixanol 270 mgI/ml
Number of subjects: 150

Group type: COMPARATOR
Intervention: ioxaglate 320 mgI/ml
Number of subjects: 150
Study: 1911585

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg orally 30 h before termination of pregnancy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 80
Study: 6210661

Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin (16 g/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intravenous ampicillin (8 g/day)
Number of subjects: 126
Study: 31232934

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 56
Study: 29282145

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition during neoadjuvant chemotherapy (NACT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care without supplemental parenteral nutrition
Number of subjects: 150
Study: 25661664

Group type: EXPERIMENTAL
Intervention: Baseline glycaemic variability measures (GV) including standard deviation (SD), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG), coefficient of variation (CV), high blood glucose index (HBGI), low blood glucose index (LBGI)
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Baseline glycaemic variability measures (GV)
Number of subjects: 1699
Study: 24300559

Group type: EXPERIMENTAL
Intervention: Cystoscopy
Number of subjects: 109
Study: 23046226

Group type: EXPERIMENTAL
Intervention: Breastfeeding education program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 60
Study: 18838420

Group type: EXPERIMENTAL
Intervention: New Zealand candidate vaccine (epidemic strain NZ98/254, B:4:P1.7b,4)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 296
Study: 17559380

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 40 mg rabeprazole
Number of subjects: 164
Study: 15449753

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil (5 microg/kg)
Number of subjects: 30
Study: 16584366

Group type: EXPERIMENTAL
Intervention: Hot water immersion (45 degrees C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ice pack application
Number of subjects: 96
Study: 10509376

Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) 5.0 mg p.o.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 2
Study: 8604671

Group type: EXPERIMENTAL
Intervention: Oral riboflavin (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral riboflavin (40 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral riboflavin (60 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous riboflavin (11.6 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control period (no riboflavin administration)
Number of subjects: 9
Study: 1824584

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 955

Group type: COMPARATOR
Intervention: Volatile anesthetics (general category)
Number of subjects: 955

Group type: COMPARATOR
Intervention: All anesthetics
Number of subjects: 955
Study: 6093270

Group type: EXPERIMENTAL
Intervention: Collagenase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 29405872

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 38
Study: 30205602

Group type: EXPERIMENTAL
Intervention: 75 g cooked whole egg (CWE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 150 g cooked whole egg (CWE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 100 g cooked whole egg (CWE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No egg
Number of subjects: 33
Study: 27187457

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP: 38% carbohydrate, 30% protein, 29% fat)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC: 53% carbohydrate, 21% protein, 23% fat)
Number of subjects: 61
Study: 24779241

Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg mifepristone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22416059

Group type: EXPERIMENTAL
Intervention: Peer led parenting intervention (Empowering parents, empowering communities), 8 weeks, 2 hours each week
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Peer led parenting intervention
Number of subjects: 116
Study: 19561542

Group type: EXPERIMENTAL
Intervention: Infliximab therapy (3-dose induction regimen)
Number of subjects: 31
Study: 17468647

Group type: EXPERIMENTAL
Intervention: PCV7 booster at 15 months
Number of subjects: 331

Group type: COMPARATOR
Intervention: PCV7 booster at 18 months
Number of subjects: 331
Study: 15883741

Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg once daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12517615

Group type: EXPERIMENTAL
Intervention: Supine position for 3 days after the operation (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sitting position on the day after the operation (Group B)
Number of subjects: 46
Study: 9501815

Group type: EXPERIMENTAL
Intervention: Neurolytic coeliac plexus block (NCPB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 24
Study: 7711146

Group type: EXPERIMENTAL
Intervention: Glucose/xylitol mixture (1:1) (C II)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glucose (C I)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isotonic saline (C III)
Number of subjects: 23
Study: 30720599

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 116
Study: 28348195

Group type: EXPERIMENTAL
Intervention: 12 hours per week Early Start Denver Model (ESDM) intervention by trained therapists (10 hours in center, 2 hours in natural environment)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Care available in the community (Control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 12 hours per week Early Start Denver Model (ESDM) intervention
Number of subjects: 180
Study: 25061714

Group type: EXPERIMENTAL
Intervention: SOC therapy + vitamin D3 (Cholecalciferol) 15,000 IU/week
Number of subjects: 101

Group type: COMPARATOR
Intervention: SOC therapy (Peg-interferon alfa-2b plus ribavirin)
Number of subjects: 101
Study: 23398616

Group type: EXPERIMENTAL
Intervention: Structured communication intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: No structured communication intervention
Number of subjects: 52
Study: 21705959

Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.32% of total fatty acids as DHA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.64% of total fatty acids as DHA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.96% of total fatty acids as DHA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.32% and 0.64% of total fatty acids as DHA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Unsupplemented formula (0.00% of total fatty acids as DHA)
Number of subjects: 122
Study: 19910316

Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac output monitoring (NICOM)
Number of subjects: 47
Study: 16968576

Group type: EXPERIMENTAL
Intervention: Once-daily ofloxacin otic solution (0.3%)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension (four times daily)
Number of subjects: 278
Study: 15282009

Group type: EXPERIMENTAL
Intervention: Epi-No birth training device
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (primigravid non-users)
Number of subjects: 48
Study: 11282262

Group type: EXPERIMENTAL
Intervention: Sitafloxacin (400 mg once daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500 mg three times daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study: 9248383

Group type: EXPERIMENTAL
Intervention: Nursing maneuvers (suctioning, bathing and turning)
Number of subjects: 22
Study: 8505664

Group type: EXPERIMENTAL
Intervention: High calcium diet (total calcium intake of 2200 mg/d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low calcium diet (240 mg Ca/d)
Number of subjects: 13
Study: 3425265

Group type: EXPERIMENTAL
Intervention: PVP-iodine eye-drops as a pre-operative disinfectant
Number of subjects: 4111

Group type: COMPARATOR
Intervention: 2.5% iodine on the skin only (control group)
Number of subjects: 4111
Study: 30404973

Group type: EXPERIMENTAL
Intervention: Intensive CR group (n=18; CR participation ≥twice/week, daily PA ≥9,000 steps)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard CR group (n=14; CR participation ≥once/2weeks, daily PA ≥6,000 steps)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients classified by median PA (7,000 steps)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with higher PA (≥7,000 steps)
Number of subjects: 32
Study: 26884352

Group type: EXPERIMENTAL
Intervention: estradiol valerate (E2V)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: conjugated equine estrogen (CEE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: isoflavones
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 25440306

Group type: EXPERIMENTAL
Intervention: Family-based therapy (FBT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Adolescent-focused individual therapy (AFT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both treatments (FBT and AFT)
Number of subjects: 79
Study: 22796132

Group type: COMPARATOR
Intervention: 40 mg esomeprazole twice daily + aspirin placebo once daily (arm A; n = 30)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole twice daily + 81 mg aspirin once daily (arm B; n = 47)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole twice daily + 325 mg aspirin once daily (arm C; n = 45)
Number of subjects: 114
Study: 20506932

Group type: EXPERIMENTAL
Intervention: Computerized bioterrorism education and training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard bioterrorism education and training program
Number of subjects: 0
Study: 18559649

Group type: EXPERIMENTAL
Intervention: Artemisone 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone 80 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone 40 mg (multiple doses for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone 80 mg (multiple doses for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone (ex vivo pharmacodynamic activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemisone (bioassay)
Number of subjects: 0
Study: 15679068

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate, 3 mg/kg over 3 days every 4 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral alendronate
Number of subjects: 12
Study: 12826145

Group type: EXPERIMENTAL
Intervention: Gengraf (generic formulation of cyclosporine)
Number of subjects: 41
Study: 10543669

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (n=1538)
Number of subjects: 3083

Group type: COMPARATOR
Intervention: No radiotherapy (n=1545)
Number of subjects: 3083
Study: 7573711

Group type: EXPERIMENTAL
Intervention: 12-day treatment with 6 mg of DEC/kg of body weight (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of 6 mg of DEC/kg of body weight at an interval of six months (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community level after group 1 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community level after group 2 treatment
Number of subjects: 0
Study: 2044527

Group type: EXPERIMENTAL
Intervention: Ascending order of exercise intensities (65%, 75%, 85%, 95% VO2 max)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Descending order of exercise intensities (65%, 75%, 85%, 95% VO2 max)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Random order of exercise intensities (65%, 75%, 85%, 95% VO2 max)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exercise at standard intensity (65% or 95% VO2 max) before and after sauna bath
Number of subjects: 13
Study: 6810734

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31511706

Group type: EXPERIMENTAL
Intervention: Motor Relearning Programme
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 66
Study: 29130624

Group type: EXPERIMENTAL
Intervention: Reduced bleomycin dose (10,000 IU/m2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard bleomycin dose (15,000 IU/m2)
Number of subjects: 28